Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2002-12-13
2004-11-09
Wilson, James O. (Department: 1623)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S028700, C536S028800
Reexamination Certificate
active
06815542
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to the field of nucleoside analogs.
BACKGROUND OF THE INVENTION
Ribavirin (1-&bgr;-D-ribofuranosyl-1,2,4-triazole-3-carboxamide) is a nucleoside analog that has demonstrated efficacy in treating viral diseases both as monotherapy (respiratory syncytial virus, Hall, C. B.; McBride, J. T.; Walsh, E. E.; Bell, D. M.; Gala, C. L.; Hildreth, S.; Ten Eyck, L. G.; W. J. Hall. Aerosolized Ribavirin treatment of infants with respiratory syncytial viral infection.
N. Engl. J. Med.
1983, 308, 1443-1447), and in combination therapy with interferon-alpha (hepatitis C virus, Reichard, O.; Norkrans, G.; Fryden, A.; Braconier, J-H.; Sonnerborg, A.; Weiland, O. Randomized, double blind, placebo controlled trial of interferon alpha 2B with and without Ribavirin for chronic hepatitis C.
Lancet
1998, 351, 83-87).
Recently reported studies indicate that the in vivo utility of Ribavirin can result not only from direct inhibition of viral replication, but also from its ability to enhance T cell-mediated immunity (Hultgren, C.; Milich, D. R.; Weiland, O.; Sällberg, M. The antiviral compound Ribavirin modulates the T helper Type1/Type2 subset balance in hepatitis B and C virus-specific immune responses.
J. Gen. Virol.
1998, 79, 2381-2391; Ning, Q.; Brown, D.; Parodo, J.; Cattral, M.; Fung, L.; Gorczynski, R.; Cole, E., Fung, L.; Ding, J. W.; Liu, M. F.; Rotstein, O.; Phillips, M. J.; Levy, G. Ribavirin inhibits viral-induced macrophage production of tumor necrosis factor, interleukin-1, procoagulant activity fgl2 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response.
J. Immunol.
1998, 160, 3487-3493; Martin, M. J.; Navas, S.; Quiroga, J. A.; Pardo, M.; Carreno, V. Effects of the Ribavirin-interferon alpha combination on cultured peripheral blood mononuclear cells from chronic hepatitis C patients.
Cytokine
1998, 79, 2381-2391). This immunomodulatory effect of Ribavirin is demonstrable in vitro by measuring the levels of Type 1 cytokines produced by activated T cells from both humans and mice (Tam, R. C.; Pai, B.; Bard, J.; Lim, C.; Averett, D. R.; Phan, U. T.; Milovanovic, T. Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile.
J. Hepatol.
1999, 30, 376-382) and by other measures. The induction of a Type 1 cytokine bias by Ribavirin is functionally significant in vivo in murine systems (Tam, R. C.; Lim, C.; Bard, J.; Pai, B. Contact hypersensitivity responses following Ribavirin treatment in vivo are influenced by Type 1 cytokine polarization, regulation of IL-10 expression and costimulatory signaling.
J. Immunol.
1999, 163, 3709-3717).
Mammalian immune systems contain two major classes of lymphocytes: B lymphocytes (B cells), which originate in the bone marrow; and T lymphocytes (T cells) that originate in the thymus. B cells are largely responsible for humoral immunity (i.e., antibody production), while T cells are largely responsible for cell-mediated immunity. T cells are generally considered to fall into two subclasses, helper T cells and cytotoxic T cells. Helper T cells activate other lymphocytes, including B cells, cytotoxic T cells, and macrophages, by releasing soluble protein mediators called cytokines that are involved in cell-mediated immunity. As used herein, lymphokines are a subset of cytokines. Helper T cells are also generally considered to fall into two subclasses, Type 1 and Type 2. Type 1 cells produce interleukin 2 (IL-2), tumor necrosis factor (TNF&agr;) and interferon gamma (IFN&ggr;), and are responsible primarily for cell-mediated immunity such as delayed type hypersensitivity and antiviral immunity. In contrast, Type 2 cells produce interleukins, IL4, IL-5, IL-6, IL-9, IL-10 and IL-13, and are primarily involved in assisting humoral immune responses such as those seen in response to allergens, e.g. IgE and lgG4 antibody isotype switching (Mosmann, 1989,
Annu Rev Immunol,
7:145-173).
As used herein, the terms Type 1 and Type 2 “responses” are meant to include the entire range of effects resulting from induction of Type 1 and Type 2 lymphocytes, respectively. Among other things, such responses include variation in production of the corresponding cytokines through transcription, translation, secretion, and possibly other mechanisms, increased proliferation of the corresponding lymphocytes, and other effects associated with increased production of cytokines, including motility effects.
Previous application Ser. Nos. (09/291903, 09/471513, 60/164365, 60/164366, 60/172097, 60/175111, and 60/189672), each of which is incorporated herein by reference, relate to aspects of our recent discoveries involving the effect of various nucleosides (which are defined herein to include derivatives and analogs of native nucleosides) on selectively modulating lymphocyte responses relative to each other. Among other things, we have shown that either of the Type 1 and Type 2 responses can be selectively suppressed while the other is either induced or left relatively unaffected, and either of the Type 1 or Type 2 responses can be selectively induced while the other is either suppressed or left relatively unaffected. We have also discovered the surprising fact that some nucleosides effective in selectively modulating Type 1 and Type 2 responses relative to one another tend to have a bimodal effect. Among other things, some nucleosides that tend to generally suppress or induce both Type 1 and Type 2 activity at a relatively higher dose tend to selectively modulate Type 1 and Type 2 relative to each other at relatively lower doses.
Viramidine™ (1-&bgr;-D-ribofuranosyl-1,2,4-triazole-3-carboxamidine hydrochloride) has been shown active in ten different viruses—comparable to Ribavirin. (J. T. Witkowski, R. K. Robins, G. P. Khare, R. W. Sidwell,
J. Med. Chem.,
16, 935-937, 1973; R. W. Sidwell, J. H. Huffman, D. L. Barnard, D. Y. Pifat,
Antiviral Research,
10, 193-208, 1988; B. Gabrielsen, M. J. Phelan, L. Barthel-Rosa, C. See, J. W. Huggins, D. F. Kefauver, T. P. Monath, M. A. Ussery, G. N. Chmumy, E. M. Schubert, K. Upadhya, C. Kwong, D. A. Carter, J. A. Secrist III, J. J. Kirsi, W. M. Shannon, R. W. Sidwell, G. D. Kini, R. K. Robins,
J. Med. Chem.,
35, 3231-3238, 1992). In addition, Viramidine™, like Ribavirin, is an inhibitor of IMP dehydrogenase (R. C. Willis, R. K. Robins, J. E. Seegmiller,
Molecular Pharmacology,
18, 287-295, 1980). Furthermore, preliminary toxicology studies suggest that Viramidine™ is less toxic than Ribavirin (D. Y. Pifat, R. W. Sidwell, P. G. Canonico,
Antiviral Research,
9, 136, 1988). Also, recent studies at our lab (R. Tam, K. Ramasamy, ICN Pharmaceuticals, Inc., unpublished results, 1999) revealed that Viramidine™ and Ribavirin exhibit similar immunomodulatory properties. These results coupled with low bioavailability and the toxicity associated with Ribavirin prompt us not only to develop Viramidine™ for other viral diseases but also to prepare other derivatives of Viramidine™, including the synthesis of prodrugs of Viramidine™, and screen them as potential antiviral agents.
Ribavirin and Levovirin are similar with respect to structure, except that Levovirin is in the L-configuration of the compound and has a substantially reduced toxicity. For example, while oral administration of Ribavirin in rats at 180 mg/kg over four weeks produced significant hemolytic anemia and leukopenia, Levovirin did not produce any observable clinical pathology. Furthermore, it is contemplated that treatment of a viral disease with Levovirin is predominantly based on the modulation of the Th1/Th2 balance towards a Th1 dominated response, and not predominantly based on a direct antiviral effect. The term “direct antiviral” effect or activity as used herein refers to an immediate effect or activity of a drug on viral assembly or replication. In contrast, a reduction of viral activity or replication that is at least in part mediated by one or more components of the immune system is not considered a “direct antiviral” effect or activity. Likewise, it should be ap
Girardet Jean-Luc
Hong Zhi
Lau Johnson
Ramasamy Kanda
Brown & Raysman Millstein Felder & Steiner LLP
Owens, Jr. Howard V.
Ribapharm Inc.
Wilson James O.
LandOfFree
Nucleoside compounds and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nucleoside compounds and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleoside compounds and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3357184